KRISTEN OKUMURA: Open Payments
NPI 1912604141 · NEWTON, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$692 in 29 payments from 9 companies in 2025. Trend: 2023 $33 · 2024 $0 · 2025 $692
Food & beverage: $582Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $204 |
| Otsuka America Pharmaceutical, Inc. | 8 | $150 |
| Neurocrine BioSciences, Inc. | 5 | $87 |
| Janssen Pharmaceuticals, Inc | 3 | $80 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Alkermes, Inc. | 2 | $35 |
| Supernus Pharmaceuticals, Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $21 |
Products named: INGREZZA, REXULTI, ABILIFY MAINTENA, UZEDY, INVEGA SUSTENNA, FANAPT, AUSTEDO XR, CAPLYTA.
Industry payments across KS — which companies pay providers there.
